Elite Pharmaceuticals Shares Drop Below 200-Day Average

Analysts Recommend Looking at Other Stocks Instead of Buying ELTP

Mar. 28, 2026 at 6:51am

Got story updates? Submit your updates here. ›

Shares of Elite Pharmaceuticals (OTCMKTS:ELTP) have fallen below their 200-day moving average, signaling a potential sell signal for investors. The specialty pharmaceutical company, headquartered in Houston, Texas, has seen its stock price decline amid broader market volatility.

Why it matters

Crossing below the 200-day moving average is often seen as a bearish technical indicator, suggesting the stock may continue to struggle. With analysts recommending other pharmaceutical stocks over Elite, investors will need to carefully evaluate the company's fundamentals and future prospects.

The details

Elite Pharmaceuticals' stock price closed at $0.3704 on Friday, down from a 200-day moving average of $0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.44 and a current ratio of 7.34. Elite has a market cap of $398.96 million, a P/E ratio of 12.35 and a beta of 0.35.

  • Elite Pharmaceuticals' shares crossed below the 200-day moving average on Friday, March 28, 2026.
  • The company last reported quarterly earnings on February 17, 2026.

The players

Elite Pharmaceuticals

A U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products, with a focus on complex dosage forms and addressing unmet medical needs.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Elite Pharmaceuticals can regain the 200-day moving average in the coming weeks and months. Analysts will also be closely monitoring the company's financial performance and pipeline developments.

The takeaway

The drop below the 200-day moving average for Elite Pharmaceuticals' stock is a concerning technical signal that may prompt some investors to reevaluate their positions. With analysts recommending other pharmaceutical stocks, Elite will need to demonstrate strong fundamentals and a clear path forward to regain investor confidence.